Poolbeg Pharma plc (AIM: POLB) (OTCQB: POLBF), a biopharmaceutical company concentrating on innovative medicines for high unmet medical needs, on Wednesday revealed positive outcomes from lab-based analysis of Respiratory Syncytial Virus (RSV) drug targets. The company strategically prioritises selected RSV drug candidates based on the comprehensive data package from its artificial intelligence (AI) program.

RSV causes lung inflammation and poses a substantial health risk, especially for children under five and adults over 65. Poolbeg Pharma's advancements in RSV drug discovery hold promise in addressing this critical medical concern.

Prioritised drug candidates are under active consideration for progression, aiming to unlock value for Poolbeg Pharma. The AI-led approach demonstrates high potential, supporting the company's partnering initiatives. Poolbeg's swift identification of RSV drug candidates within 10 months showcases the efficiency of AI-led drug discovery, aligning with a global trend of increased investments by major pharmaceutical players in this field.

The company utilises a development model focusing on clinical assets and commercialising approved drugs to fund its innovative pipeline. The leadership team, bolstered by former Amryt Pharma plc members, aims to replicate past successes and generate near-term revenues. Its clinical programs target significant markets, including cancer immunotherapy-induced CRS, infectious diseases and metabolic conditions such as obesity.